{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179464","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.878362+00:00","generated_at":"2026-05-17T13:57:53.455724+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kalaris Q2 2025 net loss $11.4M; Phase 1 TH103 data expected Q4 2025","bullets":["Net loss $11.4M ($0.61/shr) vs $5.7M ($4.26/shr) in Q2 2024; no revenue in either period.","Cash $88.4M at June 30, 2025 (up from $1.6M at Dec 31, 2024) after AlloVir merger.","R&D expenses $8.4M (up from $3.2M YoY) driven by Phase 1 clinical trial initiation.","Enrolling nAMD patients in Phase 1 trial of anti-VEGF TH103; initial data expected Q4 2025.","Hired Kristine Curtiss as SVP of Clinical; over 25 years ophthalmology experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179464","json":"https://secwatch.observer/filing/0001193125-25-179464.json","markdown":"https://secwatch.observer/filing/0001193125-25-179464.md","text":"https://secwatch.observer/filing/0001193125-25-179464.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/0001193125-25-179464-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:53.455724+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}